TABLE 3.
Intralaboratory agreement summary
| Endpoint and antifungal | % of total isolates within:
|
||
|---|---|---|---|
| 1 dilution | 2 dilutions | 3 dilutions | |
| 50% inhibition | |||
| Ciclopirox | 91.8 | 96.6 | 99.3 |
| Fluconazole | 79.6 | 87.8 | 93.9 |
| Griseofulvin | 91.2 | 97.3 | 98.0 |
| Itraconazole | 73.5 | 86.4 | 95.2 |
| Posaconazole | 95.2 | 98.6 | 100 |
| Terbinafine | 84.4 | 91.2 | 97.3 |
| Voriconazole | 74.1 | 86.3 | 94.5 |
| 80% inhibition | |||
| Ciclopirox | 92.5 | 100 | 100 |
| Fluconazole | 74.8 | 83.6 | 89.0 |
| Griseofulvin | 91.8 | 96.6 | 98.3 |
| Itraconazole | 66.7 | 85.1 | 91.9 |
| Posaconazole | 89.8 | 97.3 | 100 |
| Terbinafine | 83.7 | 91.2 | 96.0 |
| Voriconazole | 74.1 | 87.4 | 96.2 |